|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endothelial and platelet markers in diabetes mellitus type 2显示文摘Diabetes mellitus(DM) is an extremely common disorder which carries a risk of vascular impairment.DM type 2(DM2) can be characterized by the dysfunction of haemostasis manifesting by stimulated coagulation process,disorder of platelet function and decreased fibrinolytic activity.These all are the reasons why DM2 is the most common acquired thrombophilia.Endothelial dysfunction along with platelet hyperactivity are unquestionably involved in the hyperactivation of platelets and clotting factors in DM.As a natural consequence of continuous investigation,many markers of endothelial dysfunction and diabetic thrombocytopathy have been identified and considered for implementation in clinical practice.Endothelial function can be assessed by the evaluation of endothelial markers,circulating molecules synthesised in various amounts by the endothelium.These markers precede the signs of evident microangiopathy.Platelets have an ethiopathogenic relation to the microangiopathy in DM.Their increased activity was confirmed in both types of DM.Predictors of endothelial and platelet disorder could improve the screening of individuals at increased risk,thus leading to the early diagnosis,appropriate treatment,as well as to the effective prevention of the complications of DM2.In the article we deal with the mechanisms involved in the pathogenesis of endothelial and platelet functional abnormalities,endothelial and platelet markers of DM2 considered for implementation in clinical practice and possibilities of their detection. | Peter Kubisz Lucia Staniaková Ján Stako Peter Galajda Marián Mokáň | 2015 | World Journal of Diabetes2015，6，3： | 3 |
| 2 | Circulating vascular endothelial growth factor in the normo- and/ or microalbuminuric patients with type 2 diabetes mel- litus显示文摘 | KUBISZ P CHUDY P STAS KO J | 2010 | Acta Diabetol2010，47，： | 1 |
| 3 | Severe hemophilia and physiologic inhibitors of coagulation显示文摘 | KUBISZ P STASKO D J DOBROTOVA M et al | 2005 | Clin Appl Thrombosis/Hemostasis2005，11，： | 1 |
| 4 | Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis 显示文摘 | Blann AD Dobrotova M Kubisz P | 1995 | Thromb Haemost1995，74，2： | 1 |
| 5 | Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus显示文摘 | Kubisz P ChudS P Stasko J | 2010 | Acta Diabetol2010，47，2： | 1 |
| 6 | Hemostasis in patients with diabetes mellitus显示文摘 | Galajda P Martinka E Kubisz P | 1996 | Vnitr Lek1996，42，11： | 1 |
| 7 | Severe hemophilia and physiologic inhibitors of coagulation显示文摘 | KUBISZ P STASKO D J DOBROTOVA M et al | 2005 | Clin Appl Thrombosis/Hemostasis2005，11，： | 1 |
| 8 | Successful immune tolerance induction consisting of high-dose factor V~ rich in von Willebrand factor and pulsed intravenous immunoglobulin: a case report 显示文摘 | KUBISZ P PLAMENOVA I HOLLY P | 2012 | J Med Case Rep2012，6，： | 1 |
| 9 | Etiological bacterial factors of respiratory system infections in the Intensive Care Unit Surgery Clinic 显示文摘 | Kubisz A Kedzierska J Kulig J | 2008 | Przegl Lek2008，65，6： | 1 |
| 10 | Von Willebrand factor, soluble P selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis显示文摘 | Blann A D Dobrotova M Kubisz P | 1995 | Thromb Haemost1995，74，2： | 1 |
| 11 | Von willebrand factor soluble p-sel-e ctin,tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis显示文摘 | Blann AD Dobrotova M Kubisz P | 1995 | Thromb Haemost1995，74，： | 1 |
| 12 | Severe hemophilia and physiologic inhibitors of coagulation显示文摘 | Kubisz P Stasko J Dobrotova M | | 0，，03： | 1 |
| 13 | Von willebrand factot,soluable P-selectin,tissue plasminogen activator and plasrninogen activator inhibitor or at herosclerosis显示文摘 | Dobrotova M Kubisz P et a1 | 1995 | Thromb Haemost1995，74，： | 1 |
| 14 | Von willebrand factor,soluble P-selectin,tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis显示文摘 | Blann AD Dobrotova M Kubisz P | 1995 | Thromb Haemost1995，74，： | 1 |
| 15 | Recombinant activated factor Ⅶ in patient at high risk of bleeding显示文摘 | Kubisz P Stasko J | 2004 | Hematology2004，9，56： | 1 |
| 16 | von Willebrand factor,soluble P selestin,tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis显示文摘 | BLANN A D DOBROTOVA M KUBISZ P | 1995 | Thromb Haemost1995，74，2： | 1 |
| 17 | Successful immune tolerance induction with high-dose coagulation factorⅧand intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factorⅧdespite unfavorable prognosis for the therapy显示文摘 | Kubisz P PlamenováI Holl P | 2009 | Med Sci Monit2009，15，6： | 1 |
| 18 | The Mordellidae ( Coleoptera: Tenebrionoidea ) of north - eastern Poland, a fannistic synopsis 显示文摘 | Kubisz DR Gawronski | 2010 | Polish Journal of Entomology2010，79，3： | 1 |
| 19 | Von willebrand factor,soluble P-selectin,tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis显示文摘 | Blann AD Dobrotova M Kubisz P | 1995 | Thromb Haemost1995，74，2： | 1 |
| 20 | Von willebrandfactor soluble p-selectin,tissue plasminogen activator and plasmiuogen activator inhibitor in atheroselerosis 显示文摘 | Blann AD Dobrotova M Kubisz P | 1995 | Thromb Haemost1995，74，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员